Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
T. ROWE PRICE GROWTH STOCK FUND, INC. et al v. VALEANT PHARMACEUTICALS INTERNATIONAL, INC., et al
Case Number:
3:16-cv-05034
Court:
Nature of Suit:
Judge:
Firms
Companies
- Alleghany Corp.
- Bausch Health Cos. Inc.
- CapSpecialty Inc.
- Pacific Compensation Insurance Co.
- Transatlantic Holdings Inc.
- T. Rowe Price Group Inc.
Sectors & Industries:
-
July 31, 2017
T. Rowe, Funds Fight Valeant's Bid To Kill Stock Drop Suits
T. Rowe Price Group Inc. and other investors asked a New Jersey federal court on Friday not to dismiss their securities suits against Valeant Pharmaceuticals International Inc., saying Valeant and its executives have rehashed the same arguments that the court rejected in a similar case.
-
June 19, 2017
Valeant Tries To Zap Claims In 4 Securities Fraud Suits
Valeant Pharmaceuticals International Inc. on Friday asked a New Jersey federal court to pare four securities fraud suits brought against it by institutional investors, arguing that some of the investors' claims are too broad or are backed up with inappropriately generic allegations.
-
August 18, 2016
T. Rowe, Alleghany Go After Valeant For Stock Drop
T. Rowe Price and Alleghany Corp. sued Valeant Pharmaceuticals International Inc. and six executives this week in New Jersey federal court for losses the investors say they suffered after the market learned of Valeant's massive scheme to trick health care insurers into paying for overpriced drugs.